Skip to main content
logo
Attovia Therapeutics, Inc. (ATTO)
NASDAQ: ATTO · Real-Time Price · USD
18.25
+1.07 (6.26%)
Oct 5, 2026, 2:24 PM EDT - Market open

Attovia Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-70.38-60.63-39.8
Depreciation & Amortization
0.940.80.31
Other Amortization
-0.39-
Loss (Gain) From Sale of Assets
00.010.01
Loss (Gain) From Sale of Investments
-1.77-2.66-0.68
Stock-Based Compensation
2.742.391.39
Other Operating Activities
0.210.222.2
Change in Accounts Payable
1.170.181.72
Change in Other Net Operating Assets
-0.350.1-0.18
Operating Cash Flow
-67.43-59.2-35.04
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-0.79-2.31-1.77
Investment in Securities
60.16-71.14-38.03
Investing Cash Flow
59.37-73.46-39.8

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Long-Term Debt Repaid
---0.17
Net Debt Issued (Repaid)
---0.17
Issuance of Common Stock
0.090.190.31
Other Financing Activities
-1.84-0.38-0.02
Financing Cash Flow
-1.75142.0182.75

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Cash Flow
-9.829.367.91

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-68.22-61.51-36.81
Free Cash Flow Growth
---
Free Cash Flow Margin
-3790.11%-4556.44%-
Free Cash Flow Per Share
-16.55-15.57-10.42
Levered Free Cash Flow
--40.21-
Unlevered Free Cash Flow
--40.21-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Change in Working Capital
0.820.281.54
SEC Filings: 10-K · 10-Q